Seuraa
Robert S. Wallis, MD, FIDSA
Robert S. Wallis, MD, FIDSA
CSO, Aurum Institute; Prof Medicine, CWRU & Vanderbilt
Vahvistettu sähköpostiosoite verkkotunnuksessa po.cwru.edu - Kotisivu
Nimike
Viittaukset
Viittaukset
Vuosi
Granulomatous infectious diseases associated with tumor necrosis factor antagonists
RS Wallis, MS Broder, JY Wong, ME Hanson, DO Beenhouwer
Clinical infectious diseases 38 (9), 1261-1265, 2004
12272004
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
RS Wallis, M Pai, D Menzies, TM Doherty, G Walzl, MD Perkins, A Zumla
The lancet 375 (9729), 1920-1937, 2010
6362010
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
I Solovic, M Sester, JJ Gomez-Reino, HL Rieder, S Ehlers, HJ Milburn, ...
European Respiratory Journal 36 (5), 1185-1206, 2010
6062010
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ...
The Lancet infectious diseases 17 (1), 39-49, 2017
4132017
Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy
CS Hirsch, Z Toossi, C Othieno, JL Johnson, SK Schwander, S Robertson, ...
Journal of Infectious Diseases 180 (6), 2069-2073, 1999
3791999
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
A Zumla, M Rao, RS Wallis, SHE Kaufmann, R Rustomjee, P Mwaba, ...
The Lancet Infectious Diseases 16 (4), e47-e63, 2016
3342016
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
RS Wallis
The Lancet infectious diseases 8 (10), 601-611, 2008
3312008
Advancing host-directed therapy for tuberculosis
RS Wallis, R Hafner
Nature Reviews Immunology 15 (4), 255-263, 2015
3302015
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
RS Wallis, M Maeurer, P Mwaba, J Chakaya, R Rustomjee, GB Migliori, ...
The Lancet infectious diseases 16 (4), e34-e46, 2016
3202016
Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection
JD Simmons, CM Stein, C Seshadri, M Campo, G Alter, S Fortune, ...
Nature Reviews Immunology 18 (9), 575-589, 2018
3162018
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
MZ Imperial, P Nahid, PPJ Phillips, GR Davies, K Fielding, D Hanna, ...
Nature medicine 24 (11), 1708-1715, 2018
3152018
Biomarkers for tuberculosis disease activity, cure, and relapse
RS Wallis, TM Doherty, P Onyebujoh, M Vahedi, H Laang, O Olesen, ...
The Lancet infectious diseases 9 (3), 162-172, 2009
313*2009
Tuberculosis biomarkers discovery: developments, needs, and challenges
RS Wallis, P Kim, S Cole, D Hanna, BB Andrade, M Maeurer, M Schito, ...
The Lancet infectious diseases 13 (4), 362-372, 2013
2982013
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection
DE Furst, R Wallis, M Broder, DO Beenhouwer
Seminars in arthritis and rheumatism 36 (3), 159-167, 2006
2782006
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis
RS Wallis, P Kyambadde, JL Johnson, L Horter, R Kittle, M Pohle, ...
Aids 18 (2), 257-264, 2004
2692004
Granulomatous infections due to tumor necrosis factor blockade: correction
RS Wallis, M Broder, J Wong, D Beenhouwer
Clinical Infectious Diseases 39 (8), 1254-1255, 2004
2682004
Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity
OY Saliu, C Sofer, DS Stein, SK Schwander, RS Wallis
The Journal of infectious diseases 194 (4), 486-492, 2006
2542006
Reactivation of latent granulomatous infections by infliximab
RS Wallis, M Broder, J Wong, A Lee, L Hoq
Clinical infectious diseases 41 (Supplement_3), S194-S198, 2005
2412005
Human immune response to Mycobacterium tuberculosis antigens
DV Havlir, RS Wallis, WH Boom, TM Daniel, K Chervenak, JJ Ellner
Infection and immunity 59 (2), 665-670, 1991
2191991
Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes
TK Blackmore, L Manning, WJ Taylor, RS Wallis
Clinical Infectious Diseases 47 (10), e83-e85, 2008
2132008
Järjestelmä ei voi suorittaa toimenpidettä nyt. Yritä myöhemmin uudelleen.
Artikkelit 1–20